Craft
OptiNose

OptiNose

Patents Pending (US)

35

Jun, 2017

Revenue

$74.7 M

FY, 2021

Market Capitalization

$308.2 M

2022-09-20

OptiNose Summary

Company summary

Overview
OptiNose develops nasal drug delivery technologies and combination drug-device therapies. It offers liquid delivery and powder delivery devices based on Bi-Directional Exhalation Delivery Systems (EDS). The company focuses on the treatment of chronic rhinosinusitis, nasal polyps, and chronic sinusitis.
Type
Public
Founded
2000
HQ
Morrisville, PA, US | view all locations
Website
https://www.optinose.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Peter K. Miller

    Peter K. Miller, Chief Executive Officer, Director

  • Ramy A. Mahmoud

    Ramy A. Mahmoud, President and Chief Operating Officer

  • Victor Clavelli

    Victor Clavelli, Chief Commercial Officer

  • Mike Marino

    Mike Marino, Chief Legal Officer

    Operating MetricsView all

    Patents Pending (US)

    35

    Jun, 2017

    Trademarks (US)

    3

    Jun, 2017

    Patents (US)

    43

    Jun, 2017

    LocationsView all

    3 locations detected

    • Morrisville, PA HQ

      United States

      1020 Stony Hill Rd #300

    • Oslo, Oslo

      Norway

      Gaustadalléen 21

    • Swindon, England

      United Kingdom

      Berkeley House, Hunts Rise

    OptiNose Financials

    Summary financials

    Revenue (Q2, 2022)
    $20.6M
    Cash (Q2, 2022)
    $78.3M
    Enterprise value
    $359.8M

    Footer menu